Sign In
Buy RCKT
$3.11
-0.100 (-3.12%)
At Close: Jul 31, 2026
Rocket Pharmaceuticals price target raised to $51 from $50 at Scotiabank
09:11am, Monday, 11'th Nov 2024
Scotiabank raised the firm's price target on Rocket Pharmaceuticals to $51 from $50 and keeps an Outperform rating on the shares. The company provided "a slew of positive updates," which included an a
Rocket Pharmaceuticals to Participate in the UBS Global Healthcare Conference
07:00am, Friday, 08'th Nov 2024
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord
Rocket: Danon Disease Treatment Program Should Carry The Tide Until Regulatory Moves
03:18pm, Thursday, 19'th Sep 2024
Enrollment completed for pivotal single-arm phase 2 study, using RP-A501 for the treatment of male patients with Danon disease. Promise for RP-A501 program lies with the potential to receive FDA Accel
RCKT Completes Enrollment in Rare Heart Disease Study, Stock Rises
11:50am, Wednesday, 18'th Sep 2024
Rocket completes enrollment of patients in a pivotal phase II study evaluating RP-A501 for treating male patients with Danon disease.
Rocket Stock Down More Than 30% in Past Six Months: Here's Why
12:05pm, Monday, 09'th Sep 2024
The recent regulatory setbacks related to RCKT's pipeline candidate, Kresladi (marnetegragene autotemcel) weigh heavily on the stock.
3 Biotech Names With Potential Catalysts By Year End
03:32pm, Monday, 29'th Jul 2024
The huge sector rotation we have seen in the market over the past few weeks has significantly benefited the SPDR® S&P Biotech ETF. If this trend continues, small-cap names within the sector should co
FDA Rejects Rocket's (RCKT) Gene Therapy BLA for Rare Disease
05:11am, Tuesday, 02'nd Jul 2024
Per the FDA, Rocket (RCKT) needs to submit additional manufacturing information on Kresladi gene therapy to secure approval for severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic disorder.
FDA Again Delays Approval of Rocket Pharmaceuticals' Gene Therapy Treatment
01:26pm, Friday, 28'th Jun 2024
Rocket Pharmaceuticals (RCKT) shares declined in intraday trading Friday after the biopharmaceutical firm announced that the Food and Drug Administration (FDA) wants more data about its gene therapy t
Rocket Pharmaceuticals Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel)
07:27am, Friday, 28'th Jun 2024
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord
Why Is Rocket Pharmaceuticals (RCKT) Down 4.8% Since Last Earnings Report?
12:35pm, Wednesday, 05'th Jun 2024
Rocket Pharmaceuticals (RCKT) reported earnings 30 days ago. What's next for the stock?
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord
Rocket's (RCKT) Q1 Loss Narrower Than Expected, Sales Nil
12:31pm, Tuesday, 07'th May 2024
Rocket Pharmaceuticals' (RCKT) first-quarter earnings beat estimates. Devoid of marketed drugs, the company did not report any revenues during the quarter.
Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress
04:01pm, Monday, 06'th May 2024
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord
Rocket Pharmaceuticals (RCKT) Upgraded to Buy: Here's Why
01:00pm, Tuesday, 30'th Apr 2024
Rocket Pharmaceuticals (RCKT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
